What GHRP-2 is
GHRP-2 activates ghrelin receptor signaling and stimulates growth hormone release in studied contexts.
GHRP-2 is grouped under Fitness + Recovery / Approved / Clinical on PeptideFactCheck because it sits in the older GH secretagogue family that shaped many modern peptide stacks and comparisons.
The useful starting point is to separate the molecule itself from the internet story around it. It is an older secretagogue that still shows up in GH-axis comparisons.
Why people keep looking it up
People discuss GHRP-2 for stronger growth-hormone release, appetite effects, recovery, and training adaptation.
GHRP-2 stimulates ghrelin receptor signaling, which can move growth hormone markers.
GHRP-2 tends to stay in the conversation because it touches a familiar public theme: ghrelin receptor, gh secretagogue, and ghsr. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Human hormone-response data exists, but outcome claims are much less settled.
Human endocrine studies support GH-release effects, but this does not validate all performance or longevity claims.
Mechanistic work supports GHSR-mediated hormone release and appetite-axis overlap.
Why this page carries the current tier: Human GH-release data exists, with limited support for broader optimization claims.
The current seed trail for GHRP-2 is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Endocrine side effects, appetite effects, and long-term use questions are central unknowns.
Regulatory status varies by country and product. Verify local approval and labeling before publication claims.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GHRP-2. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for GHRP-2 is CID 6918245. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 6918245
- Formula
- C45H55N9O6
- Molecular weight
- 818.0
- InChIKey
- HRNLPPBUBKMZMT-RDRUQFPZSA-N
Matched synonyms include Pralmorelin, 158861-67-7, GHRP-2, KP-102, D-Alanyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide, pralmorelina, pralmoreline, E6S6E1F19M.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for GHRP-2 returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for GHRP-2 returns 255 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.